Ligand buys royalty rights in pharmaceutical products and earns income from its Captisol and NITRICIL technology platforms. It last closed at $293.81 on Nov 17, down 2.62% on the day. The average 12-month price target from 3 analysts is $369.67 (+25.8% from the last close), with a high of $402.00 and a low of $350.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Each firm's latest rating on LGND in the past 90 days
Average 12-month target
$369.67
▲ 25.8% upside
Based on 3 analysts who set a price target on LGND in the past 90 days. The average target is $369.67, with a high of $402.00 and a low of $350.00, compared with the last close of $293.81.
Low $350.00Avg $369.67High $402.00
Blue marker: last close $293.81
Highest target$402.00
Average target$369.67
Lowest target$350.00
Latest rating changes
BarclaysTarget raised
Nov 11Buy$345 → $350
CitigroupTarget raised
Nov 5Buy$397 → $402
RBC CapitalTarget raised
Oct 30Buy$345 → $357
BarclaysInitiated
Sep 25Buy$345
CitigroupTarget raised
Sep 23Buy$387 → $397
Date
Firm
Action
Rating
Price target
Nov 11
Barclays
Target raised
Buy
$345 → $350
Nov 5
Citigroup
Target raised
Buy
$397 → $402
Oct 30
RBC Capital
Target raised
Buy
$345 → $357
Sep 25
Barclays
Initiated
Buy
$345
Sep 23
Citigroup
Target raised
Buy
$387 → $397
Loading…
Technical Analysis
LGND · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend
The stock is 6% below its 20 day and 3% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 14) at $292.28, and the nearest resistance the swing high (Sep 11) at $294.00.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 3.8%/day
Key levels
$326.6352 week high+11.2%
$310.6320 day average+5.7%
$302.1350 day average+2.8%
$300.37Pivot R1+2.2%
$299.68100 day average+2.0%
$295.91Pivot+0.7%
$294.00Swing high (Sep 11)+0.1%
$293.81Last close
$292.28Swing low (Oct 14)−0.5%
$289.35Pivot S1−1.5%
$259.40200 day average−11.7%
$175.8952 week low−40.1%
Indicators
RSI (14)
41.40
Middle of its range
Neutral
MACD
0.54
Below its signal line
Bearish
Stochastic
20.2
Middle of its range
Neutral
ADX (14)
15.2
No clear trend
Williams %R
-93.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-218.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−6.3%
Change over 10 sessions
Bearish
ATR (14)
$11.19
Typical daily range, 3.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumNeutral
StretchNormal
VolatilityNormal, 7.1%/day
Key levels
$326.6352 week high+11.2%
$310.6320 day average+5.7%
$302.1350 day average+2.8%
$300.37Pivot R1+2.2%
$299.68100 day average+2.0%
$295.91Pivot+0.7%
$294.00Swing high (Sep 11)+0.1%
$293.81Last close
$292.28Swing low (Oct 14)−0.5%
$289.35Pivot S1−1.5%
$259.40200 day average−11.7%
$175.8952 week low−40.1%
Indicators
RSI (14)
54.77
Middle of its range
Neutral
MACD
15.33
Below its signal line
Bearish
Stochastic
58.7
Middle of its range
Neutral
ADX (14)
27.6
Trending up
Williams %R
-58.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
7.5
Oversold below −100, overbought above 100
Neutral
Rate of change
+3.3%
Change over 10 sessions
Bullish
ATR (14)
$20.93
Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for LGND
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LGND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow LGND usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LGND has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LGND is in one of them and how their past LGND trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical royalty company based in San Diego, California. It buys and structures royalty interests in medicines that are in clinical development or already on the market, earning income from sales made by partner drugmakers. It also earns royalties and material sales from its Captisol and NITRICIL technology platforms. Its customers are mainly biopharmaceutical companies that develop and sell the medicines tied to its royalty streams.